Icotrokinra在首次报告的头对头试验中显示出优于Deucravacitinib的疗效,强化了这一新型靶向口服肽类药物治疗斑块性银屑病的前景。
Icotrokinra在首次报告的头对头试验中显示出优于Deucravacitinib的疗效,强化了这一新型靶向口服肽类药物治疗斑块性银屑病的前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.